Transdermal Delivery of Methotrexate Using Mixed Grades of Eudragit: Physico-Chemical, In-Vitro, and In-Vivo Evaluations

REFERENCES

• Monkhouse DC, Haq AS. Transdermal drug delivery—problems and promises. Drug Dev Ind Pharm 1988; 14: 183–209
   Web of Science ®Google Scholar
• Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Del. 2006; 13: 175–187
   PubMed Web of Science ®Google Scholar
• Kurihara BT, Good WR, Feusullin S, Signor C. Skin compatibility of transdermal drug delivery system. J Control Release. 1991; 15: 271–278
   Web of Science ®Google Scholar
• Chandak AR, Verma PRP. Formulation and characterization of eudragit based methotrexate transdermal delivery system. National Symposium on Controlled Release in Infection and Cancer, CRS (Indian Chapter), CDRI, LucknowIndia June 18, 2007
   Google Scholar
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57: 163–172
   PubMed Web of Science ®Google Scholar
• Dollery C. Therapeutic Drugs2d. Churchill Livingstone, Edinburgh 1999; 2: M90–M96
   Google Scholar
• Chartterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on the in-vitro and in-vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res. 1997; 14: 1058–1065
   PubMed Web of Science ®Google Scholar
• Anderson SE, Johansson L-H, Lexmuller K, Ekstrom GM. Anti-arthritic effect of methotrexate: is it really mediated by adenosine?. Euro J Pharm Sci. 2000; 9: 333–343
   PubMed Web of Science ®Google Scholar
• Hikima T, Tojo K, Maibach HI. Skin metabolism in transdermal therapeutic systems. Skin Pharmacol Physiol. 2005; 18: 153–159
   PubMed Web of Science ®Google Scholar
• Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of eudragit: design and in vitro and in vivo evaluation. Drug Dev Ind Pharm 2000; 26: 471–476
   PubMed Web of Science ®Google Scholar
• Murthy TEGK, Verma PRP. Controlled transdermal delivery of flurbiprofen films using mixed grades of eudragit: design, in-vitro and in-vivo evaluation. Int J Pharm Adv. 1996; 1: 391–397
   Google Scholar
• Kotiyan PN, Vavia PR. Eudragit: role as crystallization inhibitors in drug-in-adhesive transdermal system of estradiol. Eur J Pharm Biopharm. 1993; 52: 173–180
   Google Scholar
• Iyer BV, Vasavada RC. Evaluation of lanolin alcohol films and kinetics of triamcinolone acetonide release. J Pharm Sci. 1979; 68: 782–787
   PubMed Web of Science ®Google Scholar
• Verma PRP, Iyer SS. Controlled transdermal delivery of propanolol using HPMC matrices: design, in-vitro and in-vivo evaluation. J Pharm Pharmacol. 2000; 52: 151–156
   PubMed Web of Science ®Google Scholar
• Verma PRP, Murthy TEGK. Transdermal flurbiprofen delivery using HPMC matrices: design, in-vitro and in-vivo evaluation. Drug Dev Ind Pharm. 1997; 23: 633–638
   Web of Science ®Google Scholar
• Verma PRP, Patel RK. Verapamil releasing transdermal drug delivery using HPMC matrices: design in-vitro and in-vivo evaluation. Pharm Sci. 1996; 2: 461–465
   Google Scholar
• Man M, Chang C, Lee PH, Broman CT, Cleary GW. New improved paddle method for determining the in-vitro drug release profiles of transdermal delivery systems. J Control Rel. 1993; 27: 59–68
   Web of Science ®Google Scholar
• Mansilla AE, Meras ID, Madera AZ, Pedano L, Ferreyra C. Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum. J Pharm Biomed Ana. 2002; 29: 851–858
   PubMed Web of Science ®Google Scholar
• Chamberlin AR, Cheung APK, Lim P. Methotrexate. Analytical Profiles of Drug Substances, K Florey. Academic Press Inc, London, New York, San Francisco 1976; 5: 283–305
   Google Scholar
• Moffat AC. Methotrexate. Clarke's Isolation and Identification of Drugs: In Pharmaceuticals, Body Fluids, and Post-mortem Material 2nd. Pharmaceutical Press, London 1986; 756
   Google Scholar
• Wartewig S, Neubert RHH. Pharmaceutical application of mid-IR and Raman spectroscopy. Adv Drug Del Rev. 2005; 57: 1144–1170
   PubMed Web of Science ®Google Scholar
• Verma PRP, Patel RK. Transdermal drug delivery of verapamil using mixed grades of eudragit: design, in-vitro and in-vivo evaluation. Pharm Sci. 1996; 2: 269–273
   Google Scholar
• Varshosaz J, Faghihian H, Rastgoo K. Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Del. 2006; 13: 295–302
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15: 25–35
   Web of Science ®Google Scholar
• Perioli L, Ambrogi V, Rubini D, Giovagnoli S, Ricci M, Blasi P, Rossi C. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J Control Rel. 2004; 95: 521–533
   PubMed Web of Science ®Google Scholar
• Rohr UD, Altenburger R, Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering β-estradiol: in-vitro/in-vivo correlation. Pharm Res. 1998; 15: 877–882
   PubMed Web of Science ®Google Scholar
• Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci. 2004; 93: 1577–1594
   PubMed Web of Science ®Google Scholar
• McClave JT, Benson PG. Statistics for Business and Economics 4th. Maxwell and Macmillan International Editions, London & San Francisco 1990; 945–1002
   Google Scholar